Jascayd

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Idiopathic Pulmonary FibrosisInterstitial Lung Diseases

46 competitors in Idiopathic Pulmonary Fibrosis

#DrugCompanyPhaseTrials

1

Esbriet

LLegacy Health System

Approved

202

Medrol

Pfizer

Approved

13

Viagra

VViatris Specialty LLC

Approved

64

Remodulin

United Therapeutics

Approved

—5

Rapamune

PPrism Pharmaceuticals

Approved

16

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—7

Proair HFA

GGlaxo Dba Glaxosmithkline

Approved

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—9

Qvar

SSchering-Plough

Approved

—10

Rayos

RRoxane Laboratories

Approved

—Show 30 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

MPA2 trials

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

Completed·Boehringer Ingelheim·Phase 1·NCT06393127·64 enrolled

A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food

Completed·Boehringer Ingelheim·Phase 1·NCT06624072·15 enrolled

Interstitial Lung Diseases2 trials

A Double Blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nerandomilast Over at Least 26 Weeks in Patients With Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases (SARD-ILD)

Recruiting·Boehringer Ingelheim·Phase 3·NCT06806592·400 enrolled

A Double-blind, Randomized, Placebo-controlled Trial Investigating the Efficacy and Safety of Nerandomilast Over at Least 52 Weeks in Patients With Fibrosing Interstitial Lung Disease at Risk for Disease Progression (FIBRONEER-ACT)

Not yet recruiting·Boehringer Ingelheim·Phase 3·NCT07540988·466 enrolled

BOS1 trial

A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood

Completed·Boehringer Ingelheim·Phase 1·NCT07081932·16 enrolled

CAR1 trial

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Nerandomilast in the Blood

Completed·Boehringer Ingelheim·Phase 1·NCT07100964·16 enrolled

Idiopathic Inflammatory Myopathies1 trial

A Phase III, Parallel Design, Double-blind, Randomised, Placebo-controlled, Multi-centre Trial to Evaluate the Efficacy and Safety of Nerandomilast Oral Therapy Added to Standard Background Therapy Over 52 Weeks in Adult Trial Participants With Active Idiopathic Inflammatory Myopathies (VERANDA™-IIM)

Not yet recruiting·Boehringer Ingelheim·Phase 3·NCT07789015·270 enrolled

4 more indications

Interstitial Lung Disease1 trial

A Study to Evaluate the Dose-exposure, Safety, and Exploratory Efficacy of Nerandomilast in Children and Adolescents From 2 Years to Less Than 18 Years of Age With Fibrosing Interstitial Lung Disease (Part A: Double-blind, Placebo-controlled in Children From 6 to Less Than 18 Years of Age and Open-label Active Treatment in Children From 2 to Less Than 6 Years of Age), Followed by an Open-label Phase With Active Treatment (Part B)

Recruiting·Boehringer Ingelheim·Phase 3·NCT07366034·35 enrolled

Pulmonary Fibrosis1 trial

A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)

Recruiting·Boehringer Ingelheim·Phase 3·NCT07201922·80 enrolled

Idiopathic Pulmonary Fibrosis1 trial

An Open-label Extension Trial of the Long-term Safety and Efficacy of BI 1015550 Taken Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) (FIBRONEER™-ON)

Recruiting·Boehringer Ingelheim·Phase 3·NCT06238622·1,700 enrolled

Unspecified1 trial

A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men

Completed·Boehringer Ingelheim·Phase 1·NCT06139302·12 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Patent Landscape[5]

Related News